Published in Vaccine Weekly, November 21st, 2007
The initiation of Phase I was announced on Sept 25, 2006. This project is part of a contract awarded in 2005 by the U.S. Department of Health and Human Services (HHS) aimed at accelerating the development of a new cell culture- based influenza vaccine. Phase II trials involving healthy adult volunteers in the U.S. will focus further on the safety profile and immunogenicity of the cell-based vaccine.
This vaccine was developed using the PER.C6(R) cell line, licensed from Dutch...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly